Liver Cancer

Jennerex Appoints Bob Ingram Special Advisor and Hires Marty Glick as EVP, Corporate Strategy

Liver Cancer Library Library Home This article was published in Biotech Business Week, which you can subscribe to online.

Bob Ingram is Vice Chairman, Pharmaceuticals at GlaxoSmithKline (plc), and previously served as Chief Executive Officer, Chief Operating Officer and President of Pharmaceutical operations for Glaxo Wellcome. Mr. Ingram is Chairman of the Board of Directors of OSI Pharmaceuticals, Inc. and Valeant Pharmaceuticals International, and a member of the Board of Directors of Allergan, Inc., Lowe's Companies, Edwards Lifesciences Corporation, and Wachovia Corporation.

"We are delighted to welcome Bob to the Jennerex team. His experience in leading companies which have successfully developed and commercialized major new medicines adds significant strategic depth to our team," said Brennan Mulcahy, Chairman of Jennerex.

"I am excited to work with the Board and CEO of Jennerex to develop and commercialize a new class of biotherapeutics for the treatment of several major types of cancer," said Bob Ingram.

"We know Bob's extensive pharmaceutical leadership experience will be invaluable to Jennerex as we leverage our innovative technology platform to develop and commercialize major new medicines to treat patients with serious unmet needs in oncology, including liver cancer, melanoma and lung cancer," said David H. Kirn, M.D., President and Chief Executive Officer.

Mr. Glick was Executive Vice President and Chief Financial Officer of Theravance, Inc. until 2005. He led the efforts to successfully raise over $350 million of private and public equity and to form an innovative strategic alliance with GlaxoSmithKline. Prior to Theravance, Mr. Glick held the position of Vice President Finance at Genentech Inc where he was involved in structuring major deals such as in-licensing of Rituxan(R) from Idec (now Biogen Idec). Marty was also a co-founder and Board member of Eyetech Pharmaceuticals.

"Marty's experience in working with top management to successfully finance and build emerging biopharmaceutical companies is an important addition to our team as we drive our lead product candidate toward late stage clinical development and commercialization," said Dr. Kirn.

Keywords: Biopharmaceuticals, Biotechnology, Biotechnology Business, Biotechnology Company, Biotherapeutics, Drugs, Liver Cancer, Liver Carcinoma, Lung Cancer, Lung Neoplasms, OSI Pharmaceuticals Inc., Oncology, Pharmaceutical Business, Pharmaceutical Company, Pharmaceuticals, Therapies, Valeant Pharmaceuticals International, Jennerex Inc.

This article was prepared by Biotech Business Week editors from staff and other reports. Copyright 2007, Biotech Business Week via NewsRx.com.